These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25202920)

  • 1. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
    Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
    Sekar V; Lavreys L; Van de Casteele T; Berckmans C; Spinosa-Guzman S; Vangeneugden T; De Pauw M; Hoetelmans R
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4440-5. PubMed ID: 20660678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers.
    Morgan RE; Campbell SE; Suehira K; Sponseller CA; Yu CY; Medlock MM
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):158-64. PubMed ID: 22627182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers.
    Yu CY; Campbell SE; Sponseller CA; Small DS; Medlock MM; Morgan RE
    Clin Drug Investig; 2014 Jul; 34(7):475-82. PubMed ID: 24825411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
    Sekar VJ; De Pauw M; Mariën K; Peeters M; Lefebvre E; Hoetelmans RM
    Antivir Ther; 2007; 12(4):509-14. PubMed ID: 17668559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
    la Porte CJ; Sabo JP; Béïque L; Cameron DW
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
    Kiser JJ; Gerber JG; Predhomme JA; Wolfe P; Flynn DM; Hoody DW
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):570-8. PubMed ID: 18176327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
    Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
    Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
    Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
    J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.